Original-Research: NanoRepro AG (von NuWays AG): BUY
|
Original-Research: NanoRepro AG - from NuWays AG
Classification of NuWays AG to NanoRepro AG
Converting its CGM-distribution license into an equity stake Yesterday, NanoRepro announced the conversion of a distribution license covering a CGM-technology of FiberSense into a financial asset. Our take on this development in detail: Introducing FiberSense's and its CGM technology. FiberSense is a health care technology company, developing continuous glucose monitoring (CGM) technology, which collects data on a user's glucose level through sensors and passes it on to smart phones or insulin pumps. Methods of this type have effectively replaced traditional blood sample approaches and are already the standard of care for type I diabetic patients in Germany. The addressable market is highly attractive, anticipated to grow at a 15.4% CAGR from approx. $ 15.3 bn in 2026 to $ 31.4 bn in 2031, according to Mordor Intelligence. Importantly, FiberSense received the CE certification for its CGM system on June 10, 2026, which materially lowered its risk profile and validated years of product development efforts. The commercial market entry now looks significantly closer and provides further upside potential to FiberSense's value. License conversion and bridge financing granted. With the CE certification now granted and the way to market introduction paved for the product, NanoRepro has agreed to exchange the distribution license acquired at the price of € 3m in 2021 for an equity stake in FibreSense. Additionally, NanoRepro provided a € 1m convertible bond to aid its stake in bringing the product to the market. In our opinion, the commercial launch should follow in approximately one year (eNuW). Potential value creation. Given NanoRepro's long-standing involvement with FibreSense since its early development phase, we believe the conversion terms may have been negotiated on favorable conditions. While details of the transaction valuation have not been disclosed, recent financing rounds and transactions involving peer companies at comparable stages of development have ranged between € 70m and € 140m. Applying these benchmarks at a mid- to high-single-digit stake assumption (eNuW) would imply a conservative indicative value of approx. € 6-10m (eNuW), compared with a total contribution of € 4m, including the € 1m convertible loan. This suggests potential value creation from the transaction. Transaction rationale. We view the transaction positively, as it offers NanoRepro the opportunity to continue to benefit from the attractive commercial opportunities of the equity stake, while creating additional flexibility for FibreSense to pursue distribution channels more ideally suited to the medical product. Pending greater visibility on the final equity stake, commercialization strategy and commercial ramp-up, with FibreSense still at the pre-revenue stage, we leave our estimates and valuation unchanged. Nevertheless, the transaction highlights the potential for meaningful value creation should FibreSense achieve a valuation and commercial profile comparable to those of its peers. Based on our estimates, the implied value of the stake could correspond to approx. 7-25% of NanoRepro's current market capitalization, suggesting potentially significant embedded value. Looking forward, we expect NanoRepro to maintain its strategic focus on growing its multi-brand consumer health platform. This growth is seen to be particularly driven by organic sales growth of Paedi Protect and newkee/DKW in the short-term. Given the right opportunity and commercial progress, we may also see further progress on NanoRepros clear and proven inorganic growth strategy from increases in existing equity stakes (i. e. through the majority option on hyped about science) and bolt-on acquisitions. We maintain BUY at an unchanged PT of € 4.3. You can download the research here: nanorepro-ag-2026-06-19-update-en-05e33 For additional information visit our website: https://www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||
2349510 19.06.2026 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
| Die wichtigsten Finanzdaten auf einen Blick | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Umsatzerlöse1 | 16,93 | 162,72 | 38,49 | 3,18 | 4,47 | 16,00 | 18,00 | |
| EBITDA1,2 | 4,69 | 39,53 | 5,46 | -4,42 | -3,52 | -1,70 | 0,25 | |
| EBITDA-Marge3 | 27,70 | 24,29 | 14,19 | -138,99 | -78,75 | -10,63 | 1,39 | |
| EBIT1,4 | 2,80 | 38,81 | -4,37 | -5,34 | -3,62 | -2,80 | 0,05 | |
| EBIT-Marge5 | 16,54 | 23,85 | -11,35 | -167,93 | -80,98 | -17,50 | 0,28 | |
| Jahresüberschuss1 | 1,70 | 29,72 | -3,72 | -4,69 | -2,05 | -2,00 | -0,03 | |
| Netto-Marge6 | 10,04 | 18,27 | -9,67 | -147,48 | -45,86 | -12,50 | -0,17 | |
| Cashflow1,7 | -1,11 | 8,21 | 13,15 | -10,26 | 9,86 | -1,30 | -0,15 | |
| Ergebnis je Aktie8 | 0,13 | 2,30 | -0,29 | -0,36 | -0,16 | -0,15 | -0,01 | |
| Dividende8 | 0,00 | 0,50 | 0,15 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PanTaxAudit
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
| INVESTOR-INFORMATIONEN | ||||||
| ©boersengefluester.de | ||||||
| NanoRepro | ||||||
| WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
| 657710 | DE0006577109 | AG | 28,67 Mio € | 14.10.2008 | Halten | 9F2CRQ59+3R |
| KGV 2027e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
| 22,44 | 16,09 | 1,39 | -28,86 | 0,75 | 2,91 | 1,79 |
|
Dividende '2023 in € |
Dividende '2024 in € |
Dividende '2025e in € |
Div.-Rendite '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
| 26.08.2025 | - | 31.10.2025 | - | 18.07.2025 |
| Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
| +27,44% | +26,41% | +34,22% | +22,42% | -80,78% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.
Kontakt
